Atom Investors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Atom Investors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.03M	Buy	52,916 +12,890	+32%	+$706K	0.27%	77
2026 Q1	$2.26M	Buy	+40,026	New	+$2.33M	0.16%	216
2025 Q4	–	Sell	-5,878	Closed	-$318K	–	598
2025 Q3	$318K	Buy	+5,878	New	+$336K	0.02%	436
2023 Q4	–	Sell	-4,145	Closed	-$367K	–	457
2023 Q3	$367K	Buy	+4,145	New	+$369K	0.08%	283
2020 Q1	–	Sell	-12,397	Closed	-$1.05M	–	320
2019 Q4	$1.05M	Sell	12,397 -43,306	-78%	-$3.27M	0.09%	152
2019 Q3	$3.75M	Sell	55,703 -9,601	-15%	-$739K	0.26%	121
2019 Q2	$5.59M	Buy	+65,304	New	+$5.59M	0.36%	86

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Atom Investors's BMRN Position: Q2 2026 in Review

Atom Investors increased its BioMarin Pharmaceuticals (BMRN) stake by 32% in Q2 2026, buying an estimated $706K and bringing the position to 52,916 shares worth $3.03M. The position accounts for 0.27% of the portfolio, ranked #77.

Atom Investors first reported a position in BMRN in Q2 2019 and has held it in 7 quarters since. The position peaked at $5.59M in Q2 2019. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Atom Investors held 52,916 shares of BioMarin Pharmaceuticals worth $3.03M as of Q2 2026.
Atom Investors bought 12,890 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $706K.
BioMarin Pharmaceuticals made up 0.27% of Atom Investors's portfolio in Q2 2026, its #77 holding.
Atom Investors first reported a position in BioMarin Pharmaceuticals in Q2 2019 and has held it in 7 quarters since.
Atom Investors's BioMarin Pharmaceuticals position peaked at $5.59M in Q2 2019.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.